Valuation : Rezolute, Inc.

Market Cap 441M 380M 360M 326M 612M 42.12B 615M 4.27B 1.64B 21.43B 1.66B 1.62B 67.71B P/E 2026 *
-6.03x
P/E 2027 * -6.49x
Enterprise Value 441M 380M 360M 326M 612M 42.12B 615M 4.27B 1.64B 21.43B 1.66B 1.62B 67.71B EV / Sales 2026 *
-
EV / Sales 2027 * 191x
Free-Float
89.85%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Rezolute, Inc.

1 day+1.20%
1 week-7.86%
Current month-10.02%
1 month-8.66%
3 months+9.33%
6 months+32.70%
Current year+78.81%
1 week 3.97
Extreme 3.97
4.55
1 month 3.97
Extreme 3.97
5.64
Current year 1.87
Extreme 1.87
5.64
1 year 1.07
Extreme 1.07
11.46
3 years 0.72
Extreme 0.72
11.46
5 years 0.72
Extreme 0.72
11.46
10 years 0.72
Extreme 0.72
100
Manager TitleAgeSince
Chief Executive Officer 58 2013-01-29
Director of Finance/CFO 52 2024-01-22
Chief Operating Officer - -
Director TitleAgeSince
Chairman 58 2022-05-03
Director/Board Member 55 2019-11-19
Chairman 68 2019-02-09
Date Insider Type Main position Quantity % Market Cap. Importance
9/2/26 Tax

Executive/Senior Manager

-2,267 0.0026%
7/2/26 Tax

Chief Technology Officer

-3,062 0.0035%
7/2/26 Tax

Chief Financial Officer

-3,062 0.0035%
Change 5-day change 1-year change 3-year change Capi.($)
+1.20%-7.86%-47.05%+183.22% 436M
-2.11%-1.68%+44.52%+95.15% 68.24B
-0.23%-4.45%+30.39%+73.64% 62.23B
+1.67%+2.47%-11.23%+388.34% 27.8B
-1.05%-4.43%+30.56%+10.07% 24.86B
+0.34%-6.78%-7.27%-17.99% 24.22B
+0.43%-3.37%+14.85%-19.29% 19.36B
-3.03%-2.29%+185.12%+334.07% 17.28B
-1.94%-4.94%-5.29%+495.65% 14.46B
-2.28%-4.90%+43.64%+155.21% 14.23B
Average -0.70%-4.18%+27.82%+169.81% 27.31B
Weighted average by Cap. -0.86%-3.31%+33.73%+133.79%

Financials

2026 *2027 *
Net sales - 2.3M 1.99M 1.88M 1.7M 3.2M 220M 3.21M 22.33M 8.59M 112M 8.65M 8.46M 354M
Net income -72.7M -62.64M -59.31M -53.76M -101M -6.95B -101M -704M -271M -3.53B -273M -267M -11.17B -75.12M -64.72M -61.28M -55.55M -104M -7.18B -105M -728M -280M -3.65B -282M -276M -11.54B
Net Debt - -
Logo Rezolute, Inc.
Rezolute, Inc. is a late-stage rare disease company, which is focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). Its lead clinical asset, Ersodetug (formerly RZ358), is a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism including congenital HI and tumor HI. Ersodetug is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. Congenital is a rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas. RZ402, which is an oral plasma kallikrein inhibitor (PKI) being developed as a potential therapy for the chronic treatment of diabetic macular edema (DME). DME is a vascular complication of diabetes and a leading cause of blindness. RZ402 is designed to block bradykinin production and its resulting effects on vascular leakage and inflammation.
Employees
68
Date Price Change Volume
26-09-11 US$4.220 +1.20% 1,352,736
26-09-10 US$4.170 +2.71% 2,224,541
26-09-09 US$4.060 -7.73% 2,073,825
26-09-08 US$4.400 -3.93% 867,084
26-09-04 US$4.580 +0.88% 716,948
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
4.220USD
Average target price
7.667USD
Spread / Average Target
+81.67%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RZLT Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!